As most patients with neurological diseases are older adults and have underlying diseases, they are at high risk for adverse outcomes with coronavirus disease 2019 (COVID-19). Therefore, COVID-19 vaccination is strongly recommended for such patients. Anaphylaxis is a serious adverse reaction to vaccines, but its frequency is rare, and other adverse events are transient. We must consider the need for COVID-19 vaccines in consideration of the severity risk of COVID-19. As the effectiveness of some vaccines has been shown to wane after 4-6 months, we must consider the administration of a third vaccine as a booster.